Redox Biology · 2024 · 45 citations · 46 references
MedicineMolecular BiologyPharmacologyCellular PharmacologyChemotherapyMolecular PharmacologyAnthracycline CardiotoxicityNoncoding Rna BiologyRna ModificationAnthracycline-induced CardiomyopathyAnthracycline-induced CardiotoxicityCardiotoxicityChemotherapy-induced CardiomyopathyChronic Cardiac ToxicityDoxorubicin CardiotoxicityDoxorubicin-based TherapyMechanisms Of Cardiac Injury
Doxorubicin (DOX) is a chemotherapeutic drug, while its clinical use is greatly limited by the life-threatening cardiotoxicity. N6-methyladenosine (m6A) RNA modification participates in varieties of cellular processes. Nonetheless, it remains elusive whether m6A modification and its methyltransferase METTL3 are involved in the progression of DOX-induced cardiotoxicity (DIC). Mice were administrated with DOX (accumulative dosage of 20 mg/kg) repeatedly to establish a chronic DIC model. Cardiomyocyte-specific conditional METTL3 knockout mice were employed to evaluate the effects of altered m6A RNA modification on DIC. The effects of METTL3 on cardiomyocyte ferroptosis were also examined in response to DOX stimulation. DOX led to increased levels in m6A modification and METTL3 expression in cardiomyocytes in a c-Jun-dependent manner. METTL3-knockout mice exhibited improved cardiac function, remodeling and injury following DOX insult. Besides, inhibition of METTL3 alleviated DOX-induced iron accumulation and ferroptosis in cardiomyocytes, whereas METTL3 overexpression exerted the opposite effects. Mechanistically, METTL3 promoted m6A modification of TFRC mRNA, a critical gene governing iron uptake, and enhanced its stability through recognition of the m6A reader protein, IGF2BP2. Moreover, pharmacological administration of a highly selective METTL3 inhibitor STM2457 effectively ameliorated DIC in mice. METTL3 plays a cardinal role in the etiology of DIC by regulating cardiac iron metabolism and ferroptosis through TFRC m6A modification. Inhibition of METTL3 might be a potential therapeutic avenue for DIC.
46
Congestive heart failure in patients treated with doxorubicin
Sandra M. Swain, Fredrick S. Whaley, Michael S. Ewer · Cancer · 2003 · 2.3K citations · Full text
Medicine, Oncology, Pharmacology +15
Ferroptosis as a target for protection against cardiomyopathy
Xuexian Fang, Hao Wang, Dan Han et al. · Proceedings of the National Academy of Sciences · 2019 · 2.1K citations · Full text
Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia
Eliza Yankova, Wesley Blackaby, Mark R. Albertella et al. · Nature · 2021 · 1.3K citations · Full text
Medicine, Oncology, Pharmacology +13